
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp is poised for robust financial growth, with projected revenue for 4Q25 estimated at $84.8 million, representing a 26% increase quarter-over-quarter. The MACI product line is anticipated to experience volume growth in the low-to-mid teens, driven by a significant conversion rate of approximately 31.6% for biopsies to MACI treatments. Furthermore, the combination of an annual average selling price (ASP) increase of 300 to 500 basis points coupled with a compound annual growth rate (CAGR) of 14.8% for MACI volume suggests sustainable revenue growth in the high teens for the foreseeable future.
Bears say
The negative outlook on Vericel Corp's stock is primarily driven by revised revenue expectations for its MACI product, which have been lowered by approximately 200 basis points for FY26 and FY27. Additional concerns include potential slower adoption rates for MACI and MACI Arthro, decreasing burn care sales, and possible disruptions during the expansion of the sales force. The combination of these factors raises the risk of missing top-line expectations, which could lead to shares declining to historical low valuation levels.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares